Detailed Information

Cited 14 time in webofscience Cited 13 time in scopus
Metadata Downloads

Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registryopen access

Authors
Kim, Jung KwonKim, Sung HanSong, Mi KyungJoo, JungnamSeo, Seong IlKwak, CheolJeong, Chang WookSong, CherynHwang, Eu ChangSeo, Ill YoungLee, HakminHong, Sung-HooPark, Jae YoungChung, Jinsoo
Issue Date
Jul-2019
Publisher
John Wiley and Sons Ltd
Keywords
Korean; metastatic renal cell carcinoma; non-clear cell; prognosis; survival
Citation
Cancer Medicine, v.8, no.7, pp 3401 - 3410
Pages
10
Indexed
SCIE
SCOPUS
Journal Title
Cancer Medicine
Volume
8
Number
7
Start Page
3401
End Page
3410
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/1883
DOI
10.1002/cam4.2222
ISSN
2045-7634
Abstract
Objectives The optimal treatment strategy for metastatic non-clear cell renal cell carcinoma (mNCCRCC) is still elusive and mainly extrapolated from evidence available for metastatic clear cell renal cell carcinoma. The aim of the study was therefore to investigate the survival outcomes and prognostic factors affecting survival in patients with mNCCRCC treated with targeted therapy. Materials and methods We analyzed a total of 156 patients (8.1%) with mNCCRCC among the total cohort of 1922 patients in the Korean metastatic RCC registry. We used Kaplan-Meier curve analysis to calculate the survival estimates for first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). We also used the log-rank test to compare the different groups and multivariate Cox-proportional hazard regression analyses to evaluate the prognostic factors for survival. Results The mNCCRCC group had significantly inferior survival outcomes in terms of first-line PFS, total PFS, and CSS (all P < 0.05). We found survival benefits in patients treated with first-line vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs, first-line PFS, and total PFS, all P < 0.05), cytoreductive nephrectomy (CSS, P < 0.0001), metastasectomy (CSS, P = 0.0017), and patients with metachronous metastasis (first-line PFS, total PFS, and CSS, all P < 0.05). Liver metastasis was the only significant prognostic factor for both first-line PFS and CSS (all P < 0.05). Conclusions In the current targeted therapy era, survival of mNCCRCC is still inferior in comparison with that of mCCRCC patients. We found survival benefits in patients treated with first-line VEGF-TKIs/CN/metastasectomy, and metachronous metastasis patients.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Urology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Jae Young photo

Park, Jae Young
Ansan Hospital (Department of Urology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE